Research Frontiers

Enlicitide: The Oral Macrocyclic Peptide Aiming to Be the First Pill PCSK9 Inhibitor

Enlicitide (MK-0616) is an investigational oral macrocyclic peptide PCSK9 inhibitor. Macrocyclization enables oral bioavailability; Merck reports it is progressing toward FDA filing.

ChemVerify Editorial

9 min read

Published June 14, 2026

For laboratory research use only. Not for human consumption.

TL;DR: Enlicitide (enlicitide decanoate, formerly MK-0616) is an investigational oral macrocyclic peptide that inhibits PCSK9. According to Merck and published trial reports, its constrained ring structure, backbone modifications, and a decanoate ester give the peptide enough metabolic stability and membrane permeability to survive oral dosing — something conventional injectable PCSK9 antibodies cannot do. As of mid-2026, Merck has reported positive results across its Phase 3 CORALreef program and, per trade press, received a U.S. FDA Commissioner's National Priority Voucher in December 2025. A U.S. regulatory submission is reported as anticipated during 2026; if cleared, enlicitide could become the first oral PCSK9 inhibitor. Regulatory timelines are evolving and should be verified against primary sources.

Last verified: June 2026 — regulatory and trial details summarized from cited primary sources; verify current status before relying on dates.

How a Macrocyclic Peptide Survives Oral Dosing to Inhibit PCSK9

Most peptide drugs fail orally for two reasons: digestive proteases cleave their amide bonds, and their polar backbones do not cross the intestinal epithelium. Enlicitide is engineered to address both failure modes. It is a macrocycle — a ring-shaped peptide whose backbone is covalently closed into a loop. According to Merck, enlicitide is a small-molecule macrocyclic peptide that binds PCSK9 and blocks its interaction with the LDL receptor, leaving more LDL receptors available to clear LDL cholesterol from circulation. Reported pharmacodynamic data describe reductions in free plasma PCSK9 of more than 93%, per Merck and secondary summaries.

The chemistry that makes oral dosing possible is the ring itself plus conformational design. Cyclization removes the free N- and C-termini that exopeptidases attack and locks the molecule into a compact, rigid shape. Literature on orally bioavailable macrocyclic peptides describes the same toolkit applied to candidates beyond the classical Rule of Five: N-methylation of selected amides to reduce hydrogen-bond donors, incorporation of D-amino acids and non-natural residues to resist proteolysis, and amphipathic geometries with intramolecular hydrogen-bond networks that can shield polar groups during membrane transit. The result is a peptide that behaves more like a small molecule when crossing the gut wall while retaining target specificity more typical of a biologic.

The drug substance is reported as the decanoate ester ("decanoate" denotes a decanoic-acid ester conjugate), which secondary sources associate with enhanced oral delivery and metabolic stability. The molecular formula reported in reference databases is C92H129FN14O17 with a molar mass near 1,722 g/mol — far larger than a typical small molecule, underscoring that enlicitide occupies the 'beyond Rule of Five' chemical space where macrocyclization is the enabling strategy.

Where Enlicitide Stands in the FDA Process

According to trade press, in December 2025 the U.S. Food and Drug Administration selected enlicitide decanoate to receive a Commissioner's National Priority Voucher (CNPV), a pilot-program designation described as intended to compress review timelines for products addressing national priorities such as large unmet medical need. Industry analysts (RBC Capital Markets, as reported by trade press) reportedly estimated that the voucher could support a U.S. filing around mid-2026 with a potential decision later in 2026; Merck itself had not published a fixed submission date at the time of writing. These projections are analyst estimates, not regulatory commitments, and should be re-verified.

The regulatory package rests on the Phase 3 CORALreef program. CORALreef Lipids was reported as published in the New England Journal of Medicine, and the head-to-head CORALreef AddOn results were reported as published in the Journal of the American College of Cardiology. A large cardiovascular outcomes trial, CORALreef Outcomes (enrollment reported in the range of roughly 14,500 participants in secondary sources), is described as ongoing; cardiovascular event reduction and long-term durability are described as unproven pending that readout.

Phase 3 Data Snapshot (Chemical and Regulatory Facts Only)

Per published reports, the pivotal CORALreef Lipids trial randomized 2,912 adults 2:1 to oral enlicitide or placebo across multiple countries. The figures below summarize reported lipid-marker changes attributed to the cited sources; they are presented to characterize the molecule's pharmacology and the regulatory record, not as guidance of any kind.

Reported endpoint (CORALreef Lipids)	Result vs placebo (as reported)
LDL-C reduction at week 24 (primary)	≈55.8%
LDL-C between-group difference maintained at week 52	≈47.6 percentage points
Non-HDL-C at week 24	≈-53.4 points
ApoB at week 24	≈-50.3 points
Median lipoprotein(a) at week 24	≈-28.2 points
Free plasma PCSK9 reduction (reported)	greater than 93%

In the CORALreef AddOn comparison, enlicitide was reported to produce significantly greater LDL-C reductions at eight weeks than the oral non-statin agents bempedoic acid, ezetimibe, and the bempedoic acid/ezetimibe combination when added to background statin therapy. Reported discontinuation rates due to adverse events were described as comparable between enlicitide and placebo in CORALreef Lipids. These are trial-record characterizations, not statements about how any compound should be used.

Macrocyclic Peptide vs. Injectable PCSK9 Peptide and Antibody Drugs

Approved PCSK9 inhibitors to date have been parenteral: monoclonal antibodies dosed by subcutaneous injection and an siRNA agent that silences PCSK9 messenger RNA. Antibodies are large proteins that are degraded in the gut and cannot be taken as pills. Enlicitide differs in molecular class and route, which is the central reason the chemistry is notable.

Property	Injectable PCSK9 antibody	Enlicitide (oral macrocyclic peptide)
Molecular class	Monoclonal antibody (~150 kDa protein)	Macrocyclic peptide (~1.7 kDa)
Route	Subcutaneous injection	Oral tablet
Why it works in that route	Bypasses GI proteolysis entirely	Ring closure + backbone modifications reported to resist proteases; ester reported to aid absorption
Target interaction	Binds PCSK9 to block LDL-receptor binding	Binds PCSK9 to block LDL-receptor binding
Key chemistry enabler	Protein folding / Fc engineering	Macrocyclization, N-methylation, decanoate ester

The mechanistic target is shared — both classes prevent PCSK9 from degrading the LDL receptor — but the delivery problem is solved differently. Antibodies sidestep the gut; enlicitide is built to traverse it.

Why Manufacturing Was a Distinct Challenge: Biocatalytic Synthesis

Macrocyclic peptides of this size are difficult to manufacture at commercial scale by classical solid-phase synthesis. According to Merck, in May 2026 its scientists published a large-scale biocatalytic route in Science describing a suite of enzymes that catalyze selective peptide fragment formation, coupling, and macrocyclization, paired with crystallization-based purification. The company framed the approach as enabling synthesis that would be impractical with traditional methods and as offering efficiency and sustainability advantages. For laboratory readers, this is a notable data point on how 'beyond Rule of Five' macrocycles can be produced — enzymatic macrocyclization rather than purely chemical cyclization.

Verification Context for Research Buyers

Enlicitide is an investigational pharmaceutical candidate, not an established research-grade reference standard, and any material offered under that name in research-use-only channels cannot be assumed to match the clinical compound. Reference-standard identity and purity claims for any 'enlicitide' research material should be independently supported by a certificate of analysis (mass spectrometry for identity, HPLC for purity).

Confirm exact identity claims against the reported formula C92H129FN14O17 and molar mass near 1,722 g/mol where a vendor asserts the clinical structure.
Treat regulatory milestones (CNPV, filing, approval) as evolving — verify current status against primary sources before citing dates.
Distinguish the clinical macrocyclic peptide from unrelated linear peptides; macrocycle identity cannot be inferred from name alone.

Frequently Asked Questions

What is enlicitide?

Enlicitide (enlicitide decanoate, formerly MK-0616) is an investigational oral macrocyclic peptide reported to be developed by Merck that inhibits PCSK9, the protein that promotes degradation of LDL receptors. It is being studied as an orally administered candidate and would, if approved, be the first oral PCSK9 inhibitor.

Why can enlicitide be taken orally when other PCSK9 inhibitors are injected?

Approved PCSK9 inhibitors are large proteins (antibodies) or nucleic-acid agents that the digestive tract destroys, so they are administered by injection. Enlicitide is a much smaller macrocyclic peptide whose closed ring, backbone modifications, and decanoate ester are reported to give it the metabolic stability and membrane permeability needed to survive oral dosing and reach the bloodstream.

How does macrocyclization improve oral bioavailability and metabolic stability?

Cyclizing the peptide backbone removes the free chain ends that proteases cleave and locks the molecule into a rigid, compact conformation. Combined with techniques such as N-methylation and non-natural residues, the ring can shield polar groups and resist enzymatic degradation, allowing passive permeability and stability uncommon for conventional linear peptides.

Where is enlicitide in the FDA process as of mid-2026?

According to trade press, enlicitide received a U.S. FDA Commissioner's National Priority Voucher in December 2025, a designation described as intended to speed review. Positive Phase 3 CORALreef data are reported as published in NEJM and JACC, and a U.S. regulatory submission is reported as anticipated during 2026. Exact filing and decision dates are analyst projections; verify current status against primary regulatory sources.

What does 'decanoate' mean in enlicitide decanoate?

Decanoate refers to a decanoic-acid ester conjugated to the molecule. In enlicitide, secondary sources associate it with improved oral delivery and metabolic stability of the drug substance, distinguishing the formulated clinical compound from the parent macrocycle.

How does enlicitide differ mechanistically from statins?

Statins inhibit cholesterol synthesis (HMG-CoA reductase). Enlicitide instead binds PCSK9 and blocks it from degrading LDL receptors, leaving more receptors on the cell surface to clear LDL cholesterol — the same target as injectable PCSK9 inhibitors but via an orally bioavailable peptide. This describes the molecular mechanism, not a comparison of clinical use.

Verify your peptide source on ChemVerify — independent COA checks and price comparison for laboratory researchers.